Also known as: Isabl Technologies
Cancer tests based on whole genome and transcriptome data.
Company is active
Event Year: 2022
Company is active
Event Year: 2022
Isabl has pioneered innovative software designed to comprehensively analyze the entire genome of cancer patients. Unlike conventional genetic tests that examine only a limited number of potential mutations, Isabl's technology leverages the power of whole-genome sequencing. By processing a patient's tumor sample through an Illumina sequencer, Isabl's software can identify and analyze all mutations present within the genome. This breakthrough approach provides unparalleled insights into the underlying biology of tumors, enabling more informed treatment planning, precise diagnostics, effective disease surveillance, and the discovery of novel biomarkers. Isabl is poised to revolutionize cancer care through its comprehensive genomic analysis capabilities.
Isabl has pioneered innovative software designed to comprehensively analyze the entire genome of cancer patients. Unlike conventional genetic tests that examine only a limited number of potential mutations, Isabl's technology leverages the power of whole-genome sequencing. By processing a patient's tumor sample through an Illumina sequencer, Isabl's software can identify and analyze all mutations present within the genome. This breakthrough approach provides unparalleled insights into the underlying biology of tumors, enabling more informed treatment planning, precise diagnostics, effective disease surveillance, and the discovery of novel biomarkers. Isabl is poised to revolutionize cancer care through its comprehensive genomic analysis capabilities.
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2020
Total Raised: Unknown (Y Combinator backed)
Last Round: Winter 2020
Healthcare
Healthcare
Healthcare -> Diagnostics
Healthcare -> Diagnostics
Team size: 5
Hiring: No
Team size: 5
Hiring: No
